|
|
|
|
.
|
Beauval
JB, Ploussard G, Cabarrou B, Roumiguié M, Ouzzane A, Gas J,
Goujon A, Marcq G, Mathieu R, Vincendeau S, Cathelineau X,
Mongiat-Artus P, Salomon L, Soulié M, Méjean A, de
La Taille A, Rouprêt M, Rozet F; Committee of Cancerology of
the Association of French Urology.
Improved
decision making in intermediate-risk prostate cancer: a
multicenter study on pathologic and oncologic outcomes after
radical prostatectomy.
World
J Urol. 2017 Aug;35(8):1191-1197. doi: 10.1007/s00345-016-1979-z.
Epub 2016 Dec 16.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Beauval
JB, Cabarrou B, Gandaglia G, Patard PM, Ouzzane A, de la Taille A,
Soulié M, Briganti A, Ploussard G, Rozet F, Roumiguié
M.
External
validation of a nomogram for identification of pathologically
favorable disease in intermediate risk prostate cancer patients.
Prostate.
2017 Jun;77(8):928-933. doi: 10.1002/pros.23348. Epub 2017 Apr 2.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Buyyounouski
MK.
Prostate
cancer: stratifying intermediate-risk patients for radiotherapy.
Nat
Rev Urol. 2013 Aug;10(8):438-9. doi: 10.1038/nrurol.2013.142. Epub
2013 Jun 25.
Comment
on: Zumsteg ZS et al, A new risk classification system for
therapeutic decision making with intermediate-risk prostate cancer
patients undergoing dose-escalated external-beam radiation
therapy. [Eur Urol. 2013]
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Castle
KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh
TJ, McGuire SE, Kuban DA.
Is
androgen deprivation therapy necessary in all intermediate-risk
prostate cancer patients treated in the dose escalation era?
Int
J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):693-9. doi:
10.1016/j.ijrobp.2012.06.030. Epub 2012 Jul 25.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
D'Amico
AV.
Personalizing
the management of men with intermediate-risk prostate cancer.
Eur
Urol. 2013 Dec;64(6):903-4. doi: 10.1016/j.eururo.2013.03.038.
Epub 2013 Mar 26.
Comment
on: Zumsteg ZS et al, A new risk classification system for
therapeutic decision making with intermediate-risk prostate cancer
patients undergoing dose-escalated external-beam radiation
therapy.
[Eur
Urol. 2013]
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Gandaglia
G, Briganti A, Montorsi F.
Re:
Risk Group and Death From Prostate Cancer: Implications for Active
Surveillance in Men with Favorable Intermediate-risk Prostate
Cancer.
Eur
Urol. 2016 Feb;69(2):370. doi: 10.1016/j.eururo.2015.10.059.
Source
|
Full
text |
Similar
articles
Comment
on: Raldow
AC et
al., Risk
Group and Death From Prostate Cancer: Implications for Active
Surveillance in Men With Favorable Intermediate-Risk Prostate
Cancer. JAMA Oncol. 2015 Jun;1(3):334-40. doi:
10.1001/jamaoncol.2014.284.
Source
/
Full
text
|
|
|
.
|
Gandaglia
G, Schiffmann J, Schlomm T, Fossati N, Moschini M, Suardi N, Chun
FK, Montorsi F, Graefen M, Briganti A.
Identification
of pathologically favorable disease in intermediate-risk prostate
cancer patients: Implications for active surveillance candidates
selection.
Prostate.
2015 Sep;75(13):1484-91. doi: 10.1002/pros.23040. Epub 2015 Jul
14.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Jung
JW, Lee JK, Hong SK, Byun SS, Lee SE.
Stratification
of patients with intermediate-risk prostate cancer.
BJU
Int. 2015 Jun;115(6):907-12. doi: 10.1111/bju.12703. Epub 2015 Mar
27.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Keane
FK, Chen MH, Zhang D, Loffredo MJ, Kantoff PW, Renshaw AA, D'Amico
AV.
The
likelihood of death from prostate cancer in men with favorable or
unfavorable intermediate-risk disease.
Cancer.
2014
Jun 15;120(12):1787-93. doi: 10.1002/cncr.28609. Epub 2014 Mar 6.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Klotz L.
Stratifying Risk for Men With Low-Volume
Intermediate-Risk Prostate Cancer.
JAMA Oncol. 2018 May
31. doi: 10.1001/jamaoncol.2018.0748. [Epub ahead of print]
Comment on: Patel
HD et al, Adverse Pathologic Findings for Men Electing Immediate
Radical Prostatectomy: Defining a Favorable Intermediate-Risk
Group. JAMA Oncol. 2018 Jan 1.4(1):89-92. doi:
10.1001/jamaoncol.2017.1879.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Mihalcik
SA, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.
Comorbidity
and the Receipt of Curative Therapy for Favorable-risk Prostate
Cancer Prior to and Following the Publication of PIVOT.
Eur
Urol Focus. 2016 Mar 3. pii: S2405-4569(16)00063-8. doi:
10.1016/j.euf.2016.02.007. Epub 2016 Oct 17.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Morlacco
A, Cheville JC, Rangel LJ, Gearman DJ, Karnes RJ.
Adverse
Disease Features in Gleason Score 3 + 4 "Favorable
Intermediate-Risk" Prostate Cancer: Implications for Active
Surveillance.
Eur
Urol. 2017 Sep;72(3):442-447. doi: 10.1016/j.eururo.2016.08.043.
Epub 2016 Aug 27.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Patel HD, Tosoian JJ, Carter HB, Epstein JI.
Stratifying
Risk for Men With Low-Volume Intermediate-Risk Prostate
Cancer-Reply.
JAMA Oncol. 2018 May 31. doi:
10.1001/jamaoncol.2018.0754. [Epub ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
.
|
Patel HD, Gupta M, Tosoian JJ, Carter HB, Partin AW, Epstein JI.
Subtyping the Risk of Intermediate-Risk Prostate Cancer
for Active Surveillance Based on Adverse Pathology at Radical
Prostatectomy.
J Urol. 2018 Apr 16. pii:
S0022-5347(18)42985-0. doi: 10.1016/j.juro.2018.04.058. [Epub
ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
.
|
Patel HD, Tosoian JJ, Carter HB, Epstein JI.
Adverse
Pathologic Findings for Men Electing Immediate Radical
Prostatectomy: Defining a Favorable Intermediate-Risk Group.
JAMA Oncol. 2018 Jan 1;4(1):89-92. doi:
10.1001/jamaoncol.2017.1879.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Patel
HD, Tosoian JJ, Carter HB, Epstein JI.
Adverse
Pathologic Findings for Men Electing Immediate Radical
Prostatectomy: Defining a Favorable Intermediate-Risk Group.
JAMA
Oncol. 2017 Jul 13. doi: 10.1001/jamaoncol.2017.1879. [Epub ahead
of print]
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Raldow
AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.
Risk
Group and Death From Prostate Cancer: Implications for Active
Surveillance in Men With Favorable Intermediate-Risk Prostate
Cancer.
JAMA
Oncol. 2015 Jun;1(3):334-40. doi: 10.1001/jamaoncol.2014.284.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Ruiz-Cerdá JL, Lorenzo Soriano L, Ramos-Soler D,
Marzullo-Zucchet L, Loras Monfort A, Boronat Tormo F.
3+4 =
6? Implications of the stratification of localised Gleason 7
prostate cancer by number and percentage of positive biopsy cores
in selecting patients for active surveillance.
Actas
Urol Esp. 2017 Sep 14. pii: S0210-4806(17)30159-6. doi:
10.1016/j.acuro.2017.07.006. [Epub ahead of print] English,
Spanish.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Taneja
SS.
Re:
Risk Group and Death from Prostate Cancer: Implications for Active
Surveillance in Men with Favorable Intermediate-Risk Prostate
Cancer.
J
Urol. 2016 Aug;196(2):412-3. doi: 10.1016/j.juro.2016.05.068. Epub
2016 May 18.
Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
.
|
Taneja
SS.
Re:
The likelihood of death from prostate cancer in men with favorable
or unfavorable intermediate-risk disease.
J
Urol. 2014 Aug;192(2):422. doi: 10.1016/j.juro.2014.05.078. Epub
2014 May 14.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Saitz
TR, Liu JJ.
The
Quest for an Evidence-Based Approach to Intermediate-Risk Prostate
Cancer.
Oncology
(Williston Park). 2016 Mar 15;30(3):238-9.
Comment
on: Serrano NA et al, Favorable vs Unfavorable Intermediate-Risk
Prostate Cancer: A Review of the New Classification System
and Its Impact on Treatment Recommendations. [Oncology (Williston
Park). 2016]
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Serrano
NA, Anscher MS.
Favorable
vs Unfavorable Intermediate-Risk Prostate Cancer: A Review of the
New Classification System and Its Impact on Treatment
Recommendations.
Oncology
(Williston Park). 2016 Mar 15;30(3):229-36.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Zumsteg
ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane
CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ.
Number
of Unfavorable Intermediate-Risk Factors Predicts Pathologic
Upstaging and Prostate Cancer-Specific Mortality Following Radical
Prostatectomy: Results From the SEARCH Database.
Prostate.
2017 Feb;77(2):154-163. doi: 10.1002/pros.23255. Epub 2016 Sep 29.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Zumsteg
ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, Zelefsky
MJ.
A
new risk classification system for therapeutic decision making
with intermediate-risk prostate cancer patients undergoing
dose-escalated external-beam radiation therapy.
Eur
Urol. 2013 Dec;64(6):895-902. doi: 10.1016/j.eururo.2013.03.033.
Epub 2013 Mar 23.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Zumsteg
ZS, Spratt DE, Pei X, Yamada Y, Kalikstein A, Kuk D, Zhang Z,
Zelefsky MJ.
Short-term
androgen-deprivation therapy improves prostate cancer-specific
mortality in intermediate-risk prostate cancer patients undergoing
dose-escalated external beam radiation therapy.
Int
J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1012-7. doi:
10.1016/j.ijrobp.2012.07.2374. Epub 2012 Sep 14.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Zumsteg
ZS, Zelefsky MJ.
Short-term
androgen deprivation therapy for patients with intermediate-risk
prostate cancer undergoing dose-escalated radiotherapy: the
standard of care?
Lancet
Oncol. 2012 Jun;13(6):e259-69. doi: 10.1016/S1470-2045(12)70084-0.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe
SA, Nezolosky MD, Orio PF 3rd, King MT, Martin NE, Mouw KW, Trinh
QD, Nguyen PL.
Pathologic Outcomes of Gleason 6 Favorable
Intermediate-Risk Prostate Cancer Treated With Radical
Prostatectomy: Implications for Active Surveillance.
Clin
Genitourin Cancer. 2017 Nov 8. pii: S1558-7673(17)30329-4. doi:
10.1016/j.clgc.2017.10.013. [Epub ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
.
|
Yang
DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA,
Boldbaatar N, King MT, Martin NE, Orio PF Rd, Beard CJ, Hoffman
KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL.
Risk
of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4
Favorable Intermediate-risk Prostate Cancer.
Eur
Urol Focus. 2017 Jun 17. pii: S2405-4569(17)30148-7. doi:
10.1016/j.euf.2017.05.011. [Epub ahead of print]
Source
|
Full
text |
Similar
articles
|
|
|
THE
NUMBER OF RISK FACTORS PRESENT AT DIAGNOSIS
|
|
.
|
Kurbegovic
S, Berg KD, Thomsen FB, Gruschy L, Iversen P, Brasso K, Røder
MA.
The
risk of biochemical recurrence for intermediate-risk prostate
cancer after radical prostatectomy.
Scand
J Urol. 2017 Aug 1:1-7. doi: 10.1080/21681805.2017.1356369. [Epub
ahead of print]
Source
|
Full
text |
Similar
articles
|
|
|
|
|
|
|
